{"id":4459,"date":"2025-03-31T18:12:09","date_gmt":"2025-03-31T18:12:09","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/valganciclovir-txt\/"},"modified":"2025-03-31T18:12:09","modified_gmt":"2025-03-31T18:12:09","slug":"valganciclovir-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/valganciclovir-txt\/","title":{"rendered":"Valganciclovir.txt"},"content":{"rendered":"

CLINICAL USE <\/H3> Induction and maintenance treatment of CMV retinitis in AIDS patients Treatment (unlicensed indication) and prophylaxis of CMV disease in transplant patients

DOSE IN NORMAL RENAL FUNCTION <\/H3> Induction\/treatment: 900 mg twice daily for 21 days Maintenance\/prophylaxis: 900 mg daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 390.8 (as hydrochloride) <\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : <2 (as ganciclovir) <\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 84.6\u201394.6 (as ganciclovir) <\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp : 0.519\u20130.841 <\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp : 4.1\/67.5

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4> 40\u201359 Induction\/Treatment: 450 mg twice daily Maintenance\/Prophylaxis: 450 mg daily 25\u201339 Induction\/Treatment: 450 mg daily Maintenance\/Prophylaxis: 450 mg every 48 hours 10\u201324 Induction\/Treatment: 450 mg every 48 hours Maintenance\/Prophylaxis: 450 mg twice weekly
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Treatment: 450 mg 2\u20133 times a week Prophylaxis: 450 mg 1\u20132 times a week See \u2018Other Information\u2019

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Dialysed. See \u2018Other Information\u2019 <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Dialysed. See \u2018Other Information\u2019
  • HDF\/high flux &nbsp : Dialysed. See \u2018Other Information\u2019
  • CAV\/VVHD &nbsp &nbsp &nbsp: Likely dialysability. Dose as in GFR=10\u201324 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3> Potentially hazardous interactions with other drugs\n
  • Antibacterials: increased risk of convulsions with imipenem-cilastatin\n
  • Antivirals: possibly increased didanosine concentration; profound myelosuppression with zidovudine \u2013 avoid if possible Mycophenolate: possibly increased concentrations of both mycophenolic acid and ganciclovir Increased risk of myelosuppression with other myelosuppressive drugs

    ADMINISTRATION <\/H3>

    Reconstition<\/H4> \u2013

    Route <\/H4> Oral

    Rate of Administration <\/H4> \u2013

    Comments<\/H4> \u2013

    OTHER INFORMATION <\/H4> 900 mg valganciclovir twice daily is therapeutically equivalent to 5 mg\/kg intravenous ganciclovir twice daily Valganciclovir is a prodrug of ganciclovir Take with food if possible Manufacturer advises to avoid in severe renal impairment due to increased risk of bone marrow suppression Doses of 450 mg once or twice a week have been used to treat CMV disease in patients with GFR <10 mL\/min on dialysis Approximately 50% of ganciclovir is removed by haemodialysis .
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Induction and maintenance treatment of CMV retinitis in<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4459","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4459"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4459\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}